Drug Shortage Report for HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Report ID | 168499 |
Drug Identification Number | 02491699 |
Brand name | HYDROMORPHONE HYDROCHLORIDE INJECTION, USP |
Common or Proper name | HYDROMORPHONE HYDROCHLORIDE INJECTION, USP |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | HYDROMORPHONE HYDROCHLORIDE |
Strength(s) | 2MG |
Dosage form(s) | SOLUTION |
Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
Packaging size | 1mL |
ATC code | N02AA |
ATC description | OPIOIDS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2022-08-08 |
Actual start date | 2022-08-08 |
Estimated end date | Unknown |
Actual end date | 2022-09-30 |
Shortage status | Resolved |
Updated date | 2022-10-02 |
Company comments | This product will be placed on allocation. Contract customers will be allocated 100% of historical monthly demand. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2022-10-02 | French | Compare |
v3 | 2022-10-02 | English | Compare |
v2 | 2022-09-01 | French | Compare |
v1 | 2022-09-01 | English | Compare |
Showing 1 to 4 of 4